The BTK Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited population of 786-O cells with targeted disruption of the BTK gene. This polyclonal knockout model, derived from a clear cell renal cell carcinoma line, provides a loss-of-function system for investigating BTK-dependent signaling in a solid tumor context. The heterogeneous pool of edited cells ensures robust experimental outcomes and serves as a versatile platform for studying BTK biology beyond the hematopoietic system.
The 786-O cell line is a human kidney epithelial line originating from a primary clear cell adenocarcinoma and is widely used as a renal cell carcinoma (RCC) model. It carries a VHL tumor suppressor mutation, leading to constitutive HIF pathway activation. This genetic background makes 786-O cells particularly suitable for exploring oncogenic signaling networks involving non-receptor tyrosine kinases such as BTK, allowing dissection of BTK??s contributions to RCC pathophysiology.
BTK encodes Bruton??s tyrosine kinase, a cytoplasmic enzyme central to B-cell receptor (BCR) and innate immune signaling. Upon activation by SRC family kinases LYN and SYK, and membrane recruitment by PIP3, BTK phosphorylates PLCG2, leading to calcium flux and PRKCB-mediated NF-??B activation via the CARD11-BCL10-MALT1 complex. BTK also signals through PI3K-AKT and MAPK cascades, interacting with BLNK and PKC??. In 786-O cells, BTK may engage GNAQ and CXCR4 pathways; its disruption likely impairs downstream NF-??B, NFAT, and TFII-I transcriptional programs.
While BTK is primarily recognized for its role in B-cell development and diseases like X-linked agammaglobulinemia, emerging evidence points to its involvement in solid tumor biology. In RCC, BTK may promote proliferation, survival, and migration through NF-??B and AKT pathways. The BTK knockout 786-O polyclonal cells provide a defined genetic tool to examine these non-hematopoietic functions, enabling assessment of BTK??s impact on cancer phenotypes and sensitivity to targeted inhibitors in a VHL-mutant background.
These cells are suitable for western blotting and RT-qPCR to validate BTK knockout and assess downstream effectors like PLCG2 and PRKCB. Proliferation (MTS) and apoptosis (annexin V/PI) assays can quantify the functional consequences of BTK loss. Drug sensitivity testing with ibrutinib or next-generation BTK inhibitors, along with phospho-signaling analysis, can reveal pathway rewiring. This model thus enables detailed investigation of BTK-dependent mechanisms in renal cancer and evaluation of therapeutic strategies. For further information, contact Ascent Research.
